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Days since the first confirmed case
A B S T R A C T
Objective: Since the outbreak of the coronavirus disease 2019 (COVID-19) in December of 2019 in China,
estimating the pandemic’s case fatality rate (CFR) has been the focus and interest of many stakeholders.
In this manuscript, we prove that the method of using the cumulative CFR is static and does not reflect the
trend according to the daily change per unit of time.
Methods: A proportion meta-analysis was carried out on the CFR in every country reporting COVID-19
cases. Based on these results, we performed a meta-analysis for a global COVID-19 CFR. Each analysis was
performed using two different calculations of CFR: according to the calendar date and according to the
days since the outbreak of the first confirmed case. We thus explored an innovative and original
calculation of CFR, concurrently based on the date of the first confirmed case as well as on a daily basis.
Results: For the first time, we showed that using meta-analyses according to the calendar date and days
since the outbreak of the first confirmed case, were different.
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R.A. Ghayda et al. / International Journal of Infectious Diseases 100 (2020) 302–308 303Conclusion: We propose that a CFR according to days since the outbreak of the first confirmed case might
be a better predictor of the current CFR of COVID-19 and its kinetics.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Since the outbreak of the coronavirus disease 2019 (COVID-19)
in December of 2019 in China, COVID-19 has spread worldwide
(WHO, 2020; Zhu et al., 2020). As of August 19, 2020, 21,938,207
confirmed cases with 775,582 deaths were reported across the 216
affected countries, territories, or areas (WHO, 2020). Among other
clinical and epidemiologic features of the virus, predicting the
estimates of mortality of this pandemic is vital and indispensable.
The estimate of the case fatality rate (CFR) is defined as the
number of deaths from COVID-19 divided by the number of
confirmed COVID-19 cases. CFR was developed to understand the
mortality and epidemiological features of emerging infectious
diseases (Porta, 2008; Battegay et al., 2020), such as Severe Acute
RespiratorySyndrome-coronavirus (SARS, CFR9.6%on a global scale)
(Donnelly et al., 2003) and Middle East Respiratory Syndrome-
coronavirus (MERS, CFR 34.5%) (Fisman et al., 2014). To date, there
have been many attempts to estimate the underlying “true CFR” of
COVID-19 (Baud et al., 2020; Wilson et al., 2020; Rajgor et al., 2020;
Kim and Goel,2020; Spychalskietal., 2020; Lipsitch, 2020).However,
these published CFR are not without limitations. These estimates
need to be treated with extreme caution because each region of the
world is experiencing a different stage of the pandemic. Also, CFR is
contingent on many other factors, including the extensiveness,
detection and testing efficiency, local health and pandemic response
policies, and the condition and inclusiveness of the already existing
health systems. Failure to consider these former factors and simply
dividing the cumulative deaths from COVID-19 by cumulative
confirmed cases based on the latest global statistics available will
inevitably distort the CFR in each stage of COVID-19 in an unknown
direction, let alone fail to reveal the true dynamics of the CFR of this
disease. In addition, previously published papers (Yang et al., 2020;
Öztoprak, 2020) suggested models using CFR should be based on the
cumulative confirmed cases and deaths with a simple linear
regression analysis. However, this method of using the cumulative
number is static and does not reflect the trend according to the daily
change per unit of time. Additionally, it prevents an exact estimation
of the CFR because the number of the confirmed cases and the onset
time of the first case vary by country, and even within regions of the
same country.
Therefore, to get as close as possible to a real estimate, we
calculated the CFR of each country, concurrently based on the date
of the first confirmed case as well as on a daily basis.
Materials & methods
Proportion meta-analyses were performed to obtain the
average CFR for each day, commencing from the date of the first
confirmed case to the present, stratified by each country.
Therefore, we present unique CFR dynamics obtained by correcting
and theoretically circumventing the bias created by the fact that
each country is facing different stages of the pandemic. This
approach to the CFR provides a new insight that lays the
foundation for a proper analysis of CFR. One caveat that we
acknowledge is that many potential positive cases that were not
tested might present possible confounding variables, skewing our
results in a specific direction. At this point, it is impossible to
account for the totality of the COVID-19 cases (tested and not
tested), and this calculation is out of the scope of this study.Global data of COVID-19 confirmed cases and deaths from
COVID-19 were collected from the European Centre for Disease
Prevention and Control (ECDC, https://www.ecdc.europa.eu/en/
geographical-distribution-2019-ncov-cases), which showed each
country’s data from December 31, 2019, to August 12, 2020. The
CFR was defined as follows:
number of  deaths with COVID  19
number of  conf irmed cases of  COVID  19 100 ð%Þ
Important to note, our analysis of CFR included only cases
confirmed by molecular or serological testing. The data had blanks
since the reports from each country were not continuous on a daily
basis, especially during the early stages of the epidemic, secondary
to under-testing and under-reporting of cases. After multiple
rounds of discussions, for calculation simplicity, the blanks were
filled and processed as the number of cases in the most recent
report before the blank, rather than splitting the number of cases
equally among the missing days. We stratified the confirmed cases
and deaths from COVID-19 for each country, according to the
number of days since this country reported its first confirmed case
of COVID-19.
A proportion meta-analysis was then carried out on CFR in
every country reporting COVID-19 cases. Based on the results, we
performed a meta-analysis for a global COVID-19 CFR. Each
analysis was performed on two different calculations of CFR:
according to the cases' calendar date and according to days since
the outbreak of the first confirmed case. Every analysis was based
on reports until August 12, 2020.
For a meta-analysis of the CFR of COVID-19, MedCalc version
19.2.1 software (MedCalc Software, Ostend, Belgium, trial version)
was used to analyze the summary effects with a 95% confidence
interval (CI) and between-study heterogeneity. We performed a
proportion-meta-analysis to estimate the summary effects. The
summary effects obtained by the proportion meta-analysis of the
CFR under the fixed- and random-effect model for each data over
time were presented as figures, and the 95% CI are summarized in
the Supplementary Tables 1 and 2. As we mentioned, we used
MedCalc for the proportion of meta-analysis of the COVID-19 CFR.
MedCalc uses a Freeman-Tukey transformation to calculate
weighted summary proportions and the default random-effects
model is DerSimonian and Laird. The procedure suggested by
DerSimonian and Laird is the most commonly used method for
fitting the random-effects model for meta-analysis. This meta-
analytical method was used to pool CFR proportions. The
calculated fixed effect and random effects meta-analysis methods
were used to combine single proportions. Prior to that, proportions
were transformed using the Freeman-Tukey double arcsine
transformations. To determine the extent of variation between
the studies, we did heterogeneity tests with Higgins’ I2 statistic
(Higgins, 2003). An I2 value below 50% represented low or
moderate heterogeneity, while I2 >50% represented high hetero-
geneity (Higgins, 2003). For graphing the patterns of CFR in all
countries, RStudio version 1.3.1073 was used. We used a weighted
average to ensure the precision of the overall estimates, i.e., having
the smallest possible variance and standard variation. Our study
used the inverse variance weights of our data to give less weight to
the noisier and less relevant data. The weight for each size estimate
was proportional to the inverse of its variance, ensuring that larger
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data.
Results
The new dynamics of CFR revealed after the meta-analyses
Figure 1A and B present the following data over time: the fixed-
and the random-model results of the meta-analysis, the pooled
estimate, and the number of total cases included in each analysis.
By comparing the figures that show the time trend of CFR
stratified by the two methods, it was visually observed that the
CFRs calculated by each sorting method had different trends over
time: Figure 1A (CFR stratified by calendar date) vs. Figure 1B (CFR
stratified by days since the first confirmed case). In both figures,
results from the random- and the fixed-effect model were almost
identical; however, after they diverge, the fixed-effect model was
similar to the pooled estimates while the random-effect model
estimates were smaller. One possible explanation for the fact that
random CFR estimates were lower than the fixed estimate is that
less weight is given to countries with a small number of confirmed
cases than countries with a high number of cases. For example, the
United States has 5,141,207 confirmed cases and 164,537 deaths ins
Figure 1. Timeline of CFR worldwide among countries with COVID-19 reports until
August 12, 2020: (A) According to date and (B) According to days since the first
confirmed case.
COVID-19: Coronavirus 2019, CFR: case fatality rate, Fixed: fixed-effect model,
Random: random-effect model, Pooled: calculated CFR based on incidence and
mortality data, N: number.contrast to South Korea, with 14,714 confirmed cases and 30
deaths.
Similar to Figure 1A, in Figure 1B, the initial phase (phase 1
phase 2 in which pooled and fixed estimates increase rapidly, an
the random estimates increase slowly; phase 3A where pooled an
fixed estimates remain high, and phase 3B in which the pooled an
fixed estimates gradually decrease. There is also “the unreliabl
phase,” where the countries that have been enrolled later ar
dropping out as the day gets longer, making it difficult to interpre
It should be noted that during phases 3A and 3B, the random
estimates remains constant, slightly below 3.0%. When w
analyzed this data in May 2020, we could not see trends afte
phase 3A. From the point of view at that time, pooled and fixe
estimates tended to be quite similar, while random estimates wer
taken as far apart. As the data until August 12, 2020, was updated, 
long phase 3B appeared, and the pooled and fixed estimates at th
end of phase 3B became more similar to the random estimate
which had been constant for an extended period of time
narrowing the gap considerably. In this analysis, I2 is more tha
70% over the entire period from day 1 to day 174, suggesting tha
the random estimate is more reliable.
Figure 2 presents the trend of patients with COVID-19 accordin
to date and according to days. We obtained the time trend of CFR b
calculating pooled estimates, fixed- and random- effect estimateFigure 2. The trend of patients with COVID-19: (A) According to date and (B)
According to days.
COVID-19: Coronavirus 2019, CFR: case fatality rate, No.: number, Fixed: fixed-effect
model, Pooled: calculated CFR based on incidence and mortality data.
Figure 3. Differences in weight between (A) Fixed and (B) Random meta-analyses,
calculated to the number of patients at one point as an example 205 countries, April
24, 2020.
Random weight: Weight in random meta-analyses, Fixed weight: Weight in fixed
meta-analyses.
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confirmed case.
We analyzed the CFR trend by placing the number of confirmed
cases on the x-axis in Figure 2A. There are two contrasting phases,
one of which is the earlier phase (phase 2) in which the pooled and
fixed estimates rapidly increase until the number of cases reaches
2,198,764. After that, when the number of cases exceeds 3,130,785,
the later phase (phase 4) which the pooled and fixed estimates
gradually decrease in the form of a logarithmic function appears.
Besides, the initial phase (phase 1) a lack of regularity and the short
plateau phase (phase 3) are also observed. A similar trend appears
in the analysis according to the number of days from the date of the
first confirmed case in each country (Figure 2B); however, in this
figure, the length of the plateau phase between the two contrasting
phases 2 and 4 is longer than that of Figure 2A. Using the regression
equation for phase 4 obtained in Figure 2B, even if the number of
confirmed cases increases significantly up to 30 million, the fixed
estimate CFR is expected to remain at 2.7%.
We set the cut off to 100 confirmed COVID-19 cases to
reasonably reduce the noise in our statistical analyses. We focused
on the distribution of fixed and random weights on analyzing the
data from April 24, 2020, where the difference between fixed and
random effects was the largest. In the fixed estimate, as the
number of confirmed cases increases, a weight that increases
proportionally is given (Figure 3A). On the other hand, in random
meta-analyses, the weight was 0.6% for all countries or territories
with greater than or equal to 1,981 confirmed COVID-19 cases
(Figure 3B).
Namely, a higher weight is given to countries with a large
number of confirmed cases in the random estimate. On the other
hand, lower weight is given to countries with a low number of
cases in the fixed estimate (Figure 3A and B). Extrapolating from
our previous results, the cutoff date for the CFR chosen was March
20, 2020. This date guarantees a relative homogeneity of the data
analyzed. We discovered that most countries would have entered
the observed “second phase” of the pandemic, that is, after March
20, 2020, the fixed and random meta-analyses are divergent for
all countries, and their weight-adjustment would guarantee
consistency of the observed outcomes.
We identified four distinct phases based on our results. Figure
1A, phase 1 contains data from January 15 to March 15, 2020, phase
2 included data from March 16 to April 25, and phase 3 was from
April 26 to August 12. In phase 1, all CFRs ranged between 1% and
3.4%. However, from March 16 to April 25 (phase 2), both fixed and
pooled CFRs increased rapidly from 3.3% to 6.6% for fixed-effect
CFR and 3.4% to 7.3% for pooled CFR. From April 25, with 2,730,521
confirmed patients to May 16, both fixed and pooled CFRs
remained at 6%p and 7%, respectively (phase 3). Note that in
phase 3, we observed that the CFR starts to decrease even though
the number of confirmed patients per date continues to rise after
the total of 2,730,521 was reached. As our results demonstrated,
Figure 2A did not show a similar pattern as Figure 1A. In phase 2 of
Figure 1A, we observed a rise in the pooled and fixed model;
however, the random model does not increase steeply. This trend
was not observed in Figure 2A. This further supports our
hypothesis that CFR is not a dynamic indicator and should not
be analyzed solely using the traditional mathematical equation
based primarily on the cumulative number of patients. The trends
in Figure 2A are established using the number of confirmed cases
according to the calendar date. Therefore, its trend is a better
representation of the established healthcare systems, the testing
ability, and socioeconomic factors of the respective countries.
Figure 2B shows a similar trend with the characteristic phases 1
to 3, parallel to those in Figure 1. It showed an exploding increase
from Day 1 to Day 45 when the number of confirmed patients per
day reached 2,564,432 (phase 1). As the number of confirmedpatients increased to 4,648,514 on Day 66, the fixed CFR remained
at 5.4%, and the pooled CFR remained at 6.2%, despite the fact that
the number of confirmed patients increased rapidly.
Comparing Figure 1A and B, we found that both pooled and
fixed CFRs increased approximately 1% after adjusting the CFR
standard to the days since the first confirmed case (7.09% to 8.20%,
6.40% to 7.40%, respectively). Therefore, the CFR in the plateau
phase was approximately 1% higher in the meta-analyses by days
since the first confirmed patient compared to the meta-analyses by































































306 R.A. Ghayda et al. / International Journal of Infectious Diseases 100 (2020) 302–308early days of each country's epidemic. Analogous comparison of
Figure 2A and B revealed a similar 1% approximate increase in
phase 3, the plateau phase, between CFR by days since the first
confirmed patient compared to the meta-analyses by date.
An additional phase emerged in Figure 1B since countries with
newly emerging COVID-19 moved to the front of the onset period
as they were sorted by days (Supplementary Figure 2, see
Appendix). Similarly, the I2 value earlier reached above 50%
representing high heterogeneity at Day 15 and showed a plateau
pattern since Day 50 according to number of days (Supplementary
Figure 1B) than the calendar date. It reached above 50% on
February 25, 2020 and a marked plateau since April 12, 2020
according to the calendar date (Supplementary Figure 1A). The
heterogeneity that we observed is actually directly related to the
stage of the pandemic each country experienced at the time we
analyzed the data. That is, at the start of the pandemic, almost all
confirmed cases and associated mortality were originating and
reported exclusively from China. This is why the heterogeneity was
at 0% as expected. As the pandemic unfolded and many more
countries started experiencing it, confirmed cases and mortality
began to be reported from countries around the globe, in addition
to those coming from China. This was manifested by an expected
increase in the study’s heterogeneity.
Figure 1B identifies the time period of day 15 when the fixed-
and random- model estimates split, and the estimates of fixed-
model proceeds in a similar direction to the pooled model
estimates.
Correlations between the number of confirmed patients and CFR
Based on Figure 1, we also investigated the relationship between
CFR and the number of confirmed COVID-19 patients (Figure 2).
Figure 2A was devised using the number of patients according to the
calendar date rather than the cumulative number of patients. This
figure revealed that CFRs linearly correlated with the number of
confirmedcases; themorethe numberofconfirmed cases, the higher
the CFR. On the other hand, when the number of patients was
adjustedby days sincethe first confirmedcase, asshown inFigure 2B,
the CFR increases, as shown in Figure 1B, until the number of
confirmed patients per day reaches 1.0 million. Following this phase,
the CFR then rapidly increases between 1.0 million and 1.5 million
cases. After 2.0 million cases, a plateau pattern continues.
In Figure 2B, the blurry dots represent CFRs in the “unreliable
phase.” In this phase, CFR decreases when the number of
confirmed patients falls below 2 million. The unreliable phase
could potentially represent a new phase, a decreasing phase. The
model according to calendar date (Figure 2A), may have under-
estimated the CFR; this might be because of countries being in
different stages and thus phases of the disease.
Discussion
The estimation of the COVID-19 pandemic’s CFR has been the
focus and interest of many stakeholders as it plays a key role in
understanding this pandemic and guides appropriate responses
and efficient mitigation strategies. We propose that CFR is not a
fixed, static rate. It is rather dynamic, continually fluctuating with
time, location, and population, as confirmed in Figure 1A and B. In
this context, it is important to view CFR as a function of time, rather
than presenting CFR as a single and absolute value. Stratifying CFR
by days since the first confirmed case is a novel and innovative
attempt to uncover CFR dynamics as the epidemic unfolds. We
believe that a CFR stratified only by calendar date does not reflect
each country's true epidemic situation.
Our analysis revealed a CFR trend consisting of four distinctive
phases. Based on our results, we carefully propose that the slope ofthe epidemic model will proceed to the next four stages as follows
phase 1 or initial phase, phase 2 or rapid increase phase, phase 3 o
plateau phase, and phase 4 or decreasing phase. Based on thi
statistical trend, it is estimated that the pandemic's globa
situation will slow down from the time all countries reach phas
3, and it can be improved when the situation has reached the end o
the phase. However, as mentioned above and analyzing the data o
100 days so far, the world may remain in phase 3 as of May 2020 fo
an undetermined amount of time, and the CFR may not have ye
reached phase 4. It may take a considerable amount of time t
enter this final phase.
The method of calculating the CFR needs to be treate
cautiously, and its limitations acknowledged. The numerator an
the denominator of the CFR should be composed of patient
infected at the same time as those who died, to accuratel
represent the CFR. To overcome this restraint, Baud et al. (2020
and Wilson et al. (2020) proposed a time delay-adjusted CFR t
correct the delay between confirmation and death. They adjuste
the CFR's denominator as the number of confirmed cases 13-1
days before the measured date to calculate the number o
confirmed cases infected concurrently to those who died. Base
on these articles, researchers at Oxford University used their globa
COVID-19 CFR model according to the date since the outbreak i
Jan 2020 (The Centre for Evidence-Based Medicine, 2020
However, Oxford's calculation is also flawed since 13 to 14 day
before the date of test confirmation is not necessarily the dat
when a subject is infected (Spychalski et al., 2020). Moreover, som
cases show test positivity even after recovery. Additionally, th
stretching and overwhelming of healthcare systems creates a dela
between testing and receiving the results, thus confirming th
case. As this adjusted time-delay CFR leads the estimate to a
unknown bias (Spychalski et al., 2020; Lipsitch, 2020), we used th
conventional method to calculate CFR.
The numerator of the CFR is the number of deaths from COVID
19. We should be aware that this number is imperfect and ma
include deaths not directly caused by COVID-19, such as fata
comorbid diseases. This may lead to an overestimation of th
number relative to its true value.
In the present study, we observed unusually exaggerate
estimates from our meta-analyses in the early phase (Phase 1) o
the epidemic, both in a CFR based on the calendar date and base
on days since the first confirmed case. This is thought to be 
statistical bias, as many groups and countries with small number
were included. The studies included in the early phase of th
epidemic are mostly a bundle of data in which deaths sporadicall
occurred in small group sizes. Such data distribution may hav
severely exaggerated the meta-analyses results. Therefore, w
believe that we should aim for a more standardized an
homogenous analysis of the numbers. One method would be t
observe the results from the time when the number of confirme
cases in each country has reached a certain distinct level. As 
measure of when the results of meta-analyses become meaningfu
(the starting period of Phase 2), we presented the time when th
fixed-effect model and random-effect model coincided. In th
time-trend graph of every meta-analysis, the initial estimates o
the random-model and the fixed-model almost coincide; the
diverge at a certain point of time, which is, interestingly, Day 1
from the first case in each country.
There are inevitable errors that arise because actual confirme
cases, or COVID-19 deaths, are not properly reflected due t
differences in the medical system capabilities and the response t
the pandemic in each country. Moreover, the number of screenin
tests for COVID-19 differs by the diverse screening criteria of eac
country. The rapid spread of COVID-19 means that there are case
and deaths not accounted for and, consequently, not recorded i
the reported statistics. The screening criteria may have change
R.A. Ghayda et al. / International Journal of Infectious Diseases 100 (2020) 302–308 307and evolved as COVID-19 spreads in a country. For example, South
Korea had initially limited the screening tests to people with fever
(37.5 C or above), respiratory symptoms who had contacts with a
person returning from China, or confirmed symptomatic cases
within the last 14 days (Medicine TKAoI, 2020). But as the disease
spread, South Korea widened the screening criteria to anyone
who needed to be hospitalized based on a physician's decision
due to pneumonia from an unknown source (Medicine TKAoI,
2020).
The capability and efficiency of healthcare systems and the
testing ability of COVID-19 are also important. When the overall
testing capability for COVID-19 is limited to the most severe cases
hospitalized with severe illness, the number of confirmed COVID-
19 cases with mild symptoms and easily recoverable cases will be
underrepresented, resulting in artificially inflated CFRs. The
capability of healthcare systems is central because, in practice,
there are many examples where COVID-19 patients are concen-
trated in one geographical location. Cases of the disease in Italy
spread fast, especially in the North, with an overwhelming
proportion of individuals in need of intensive care units
(University of Tokyo Health Service Center, 2020; Speciale and
Kresge, 2020).
Other published studies have performed a meta-analysis of
observational COVID-19 studies and reported pooled incidence of
mortality. Zhao found a pooled CFR of 3.1% after analyzing 30
studies with 53000 patients (Zhao et al., 2020). Similarly, our CFR
meta-analysis calculated from the first confirmed case; we set
new standards for observing CFR and suggested the four phases of
an epidemic pattern. From these results, the overall estimated
CFR in this pandemic is expected to be at 2.9% to 3.0% in random
estimates (Figure 1B). Because the pandemic is still in progress,
however, future studies and discussions are needed to fulfill the
unmet need for consensus regarding the definition of each phase.
It would also be interesting to explore the relation between the
CFR and the number of tests performed. Specifically, it would be
of great added value to explore if a higher number of tests and
availability is associated with a lower CFR. When the CFR is
estimated by day since the first confirmed case, the estimates
could be more representative of “the true kinetics” of COVID-19
CFR by time in a country. The stages of the epidemic should be
classified by setting appropriate standards based on reliable
global data, and a discussion of setting these standards is
necessary. It is noteworthy to say that since COVID-19 is an
ongoing and unfolding pandemic, we caution that the CFR time
trend according to calendar days since the first confirmed case
cannot be used to predict future CFRs. The CFR analysis based on
the calendar date is subject to bias. The data that the analysis was
based on are dynamic and updated in real-time; however, this
information is subject to many variables. The phases that we
observed when the CFR according to calendar date is analyzed, are
contingent on the reporting of deaths in different and non-
homogeneous ways. It also depends on the testing abilities and
capabilities of each country. This is why, as we have discussed
before, the model that analyzed the CFR according to the day of
the first reported infection is a better and a more representative
model.
Our analysis was based mainly on a single source, the European
Centre for Disease Prevention and Control (ECDC). Although this is
a well-respected reference commonly used by the scientific
community for its accuracy, data transparency, and updated
information, this might have created some sampling bias.
Capturing all the cases of the COVID-19 pandemic globally is a
challenging and laborious process. Multiple resources have
provided researchers with data related to the daily unfolding
mortality and morbidity of the disease, such as the John Hopkins
University Dashboard. We did not perform a comparison betweenthese different data sources in our manuscript because of time
constraints. However, future COVID-19 related projects should aim
at doing so, to ensure the utmost accuracy and validity of the
information.
Conclusion
This report highlights that the CFR is not a fixed value; rather, it
is a dynamic value. Therefore, we strongly urge caution when
dealing with CFR values, especially in an ongoing epidemic.
Estimating the global CFR of COVID-19, we initially showed that the
CFR meta-analyses differed according to the calendar date and days
since the outbreak of the first confirmed case. We propose that a
CFR according to days since the outbreak of the first confirmed case
might be a better predictor of the current CFR of COVID-19 and its
kinetics.
Funding
This work was not supported by any agency or grant. No
financial compensation was provided to any of these individuals.
Conflicts of interest
The authors declare no conflict of interest directly applicable to
this research.
CRediT authorship contribution statement
Ramy Abou Ghayda: Conceptualization, Methodology, Valida-
tion, Formal analysis, Investigation, Resources, Data curation,
Writing - original draft, Writing - review & editing, Visualization,
Supervision. Keum Hwa Lee: Conceptualization, Methodology,
Validation, Formal analysis, Investigation, Resources, Data cura-
tion, Writing - original draft, Writing - review & editing,
Visualization, Supervision, Project administration. Young Joo
Han: Conceptualization, Methodology, Validation, Formal analysis,
Investigation, Resources, Data curation, Writing - original draft,
Writing - review & editing, Visualization. Seohyun Ryu: Concep-
tualization, Methodology, Validation, Formal analysis, Investiga-
tion, Resources, Data curation, Writing - original draft, Writing -
review & editing, Visualization. Sung Hwi Hong: Conceptualiza-
tion, Methodology, Validation, Formal analysis, Investigation,
Resources, Data curation, Writing - original draft, Writing - review
& editing, Visualization. Sojung Yoon: Writing - original draft,
Writing - review & editing, Visualization. Gwang Hun Jeong:
Writing - original draft, Writing - review & editing, Visualization.
Jinhee Lee: Writing - original draft, Writing - review & editing,
Visualization. Jun Young Lee: Writing - original draft, Writing -
review & editing, Visualization. Jae Won Yang: Writing - original
draft, Writing - review & editing, Visualization. Maria Effenberger:
Writing - original draft, Writing - review & editing, Visualization.
Michael Eisenhut: Writing - original draft, Writing - review &
editing, Visualization. Andreas Kronbichler: Writing - original
draft, Writing - review & editing, Visualization. Marco Solmi:
Writing - original draft, Writing - review & editing, Visualization.
Han Li: Writing - original draft, Writing - review & editing,
Visualization. Louis Jacob: Writing - original draft, Writing -
review & editing, Visualization. Ai Koyanagi: Writing - original
draft, Writing - review & editing, Visualization. Joaquim Radua:
Writing - original draft, Writing - review & editing, Visualization.
Jae Il Shin: Conceptualization, Methodology, Validation, Formal
analysis, Investigation, Resources, Data curation, Writing - original
draft, Writing - review & editing, Supervision, Project administra-
























308 R.A. Ghayda et al. / International Journal of Infectious Diseases 100 (2020) 302–308Acknowledgments
None.
Appendix B. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.ijid.2020.08.065.
References
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of
mortality following COVID-19 infection. Lancet Infect Dis 2020;20(7):773, doi:
http://dx.doi.org/10.1016/s1473-3099(20)30195-x.
Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-
novel coronavirus (2019-nCoV): estimating the case fatality rate – a word of
caution. Swiss Med Wkly 2020;150:w20203, doi:http://dx.doi.org/10.1016/
s1473-3099(20)30195-x.
Donnelly A, Azra G, Gabriel L, Hedley AJ, Fraser C, Riley S, et al. Epidemiological
determinants of spread of causal agent of severe acute respiratory syndrome in
Hong Kong. Lancet 2003;361(9371):1761–6, doi:http://dx.doi.org/10.1016/
s0140-6736(03)13410-1.
Fisman D, Rivers C, Lofgren E, Majumder MS. Estimation of MERS-coronavirus
reproductive number and case fatality rate for the Spring 2014 Saudi Arabia
Outbreak: insights from publicly available data. PLoS Curr 2014;6:, doi:http://
dx.doi.org/10.1371/currents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c
ecurrents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c.
Kim DD, Goel A. Estimating case fatality rates of COVID-19. Lancet Infect Dis
2020;20(7):773–4, doi:http://dx.doi.org/10.1016/s1473-3099(20)30234-6.
Higgins JP. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–
60, doi:http://dx.doi.org/10.1136/bmj.327.7414.557.
Lipsitch M. Estimating case fatality rates of COVID-19. Lancet Infect Dis 2020;20
(7):775, doi:http://dx.doi.org/10.1016/S1473-3099(20)30245-0.Medicine TKAoI. Version February 18, 2020. 2020. https://www.kaim.or.kr/bb
index.html?code=corona&category=&gubun=&page=1&number=12025&mo-
de=view&keyfield=&key=.
Öztoprak F. Case fatality rate estimation of COVID-19 for European Countrie
Turkey’s current scenario amidst a global pandemic; comparison of outbreak
with European countries. EJMO 2020;4(2):149–59, doi:http://dx.doi.org
10.14744/ejmo.2020.60998.
Porta M. A dictionary of epidemiology. 5th ed. Oxford: Oxford University Press; 200
Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of th
COVID-19 case fatality rate. Lancet Infect Dis 2020;20(7):776–7, doi:http://d
doi.org/10.1016/s1473-3099(20)30244-9.
Speciale A, Kresge N. Virus spread pushes Italian hospitals toward breaking poin
vol. 2020. Bloomberg; 2020.
Spychalski P, Bła _zynska-Spychalska A, Kobiela J. Estimating case fatality rates o
COVID-19. Lancet Infect Dis 2020;20(7):774–5, doi:http://dx.doi.org/10.1016
s1473-3099(20)30246-2.
The Centre for Evidence-Based Medicine. Global Covid-19 case fatality rates 
updated May 15. 2020. . [Assessed 17 May 2020] https://www.cebm.net/covid
19/global-covid-19-case-fatality-rates/.
The University of Tokyo Health Service Center. Novel Coronavirus related illness (COVID
19) 2020;vol. 2020:. https://www.u-tokyo.ac.jp/en/general/COVID-19.html.
Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-fatality risk estimates for COVID
19 calculated by using a lag time for fatality. Emerg Infect Dis 2020;26(6):1339
441, doi:http://dx.doi.org/10.3201/eid2606.200320.
World Health Organization. Coronavirus disease (COVID-19) outbreak. 2020
[Accessed 19 Aug 2020] https://covid19.who.int/.
Yang S, Cao P, Du P, Wu Z, Zhuang Z, Yang L, et al. Early estimation of the case fatalit
rate of COVID-19 in mainland China: a data-driven analysis. Ann Transl Me
2020;8(4):128, doi:http://dx.doi.org/10.21037/atm.2020.02.66.
Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, et al. Incidence, clinical characteristics an
prognostic factor of patients with COVID-19: a systematic review and meta
analysis. medRxiv 2020;, doi:http://dx.doi.org/10.1101/2020.03.17.2003757
2020.03.17.20037572.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patien
with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–33, doi:http:
dx.doi.org/10.1056/NEJMoa2001017.
